In view of HCFA's national policy, the BTA test may not be covered for screening for bladder cancer. Coverage may only be extended for its use in patients with a prior or known diagnosis of bladder cancer. Therefore, it will be allowed for follow-up oftreatment for bladder cancer, to monitor for eradication of the cancer, or recurrences after eradication. 233.7 Carcinoma in situ of the bladder. V10.51 Personal history of malignant neoplasm, bladder.
Diagnostic codes are to be used at their highest level of specificity.
Fourth and fifth digits should be utilized when they are available. EMC and hard copy claims will be monitored for appropriateness and frequency. Medicare Carriers Manual . Communication from Bard Urological Division. The test should be reported with CPT code 83516 until a specific code is developed for this test.